Latest news with #PowerfulMedical
Globe and Mail
16-05-2025
- Business
- Globe and Mail
Acute Myocardial Infarction Market to Evolve with Novel Therapies and Strategic Advancements by 2034
The Acute Myocardial Infarction (AMI) market is undergoing transformative change, spurred by advancements in rapid diagnostic technologies, personalized treatment approaches, and cardioprotective therapeutics. DelveInsight's latest AMI market report explores epidemiological trends and current treatment practices, along with pipeline innovations aimed at reducing infarct size and improving long-term cardiovascular outcomes. The ' Acute Myocardial Infarction Market Report ' by DelveInsight offers a robust analysis of market size, treatment algorithms, and unmet needs across the 7MM, providing stakeholders with actionable insights to navigate a highly competitive and evolving cardiovascular space. Some of the Key Facts of the Acute Myocardial Infarction Market Report: • The AMI market in the 7MM is valued at USD 1.6 billion in 2023, with expected strong growth. • In 2023, the U.S. had ~823K incident AMI cases, projected to rise by 2034. • LODOCO, FDA-approved by AGEPHA Pharma, is the first treatment targeting residual inflammatory risk in cardiovascular disease. • NSTEMI cases (~607K) outnumbered STEMI cases in the U.S. in 2023. • In March 2025, Powerful Medical, a leader in AI-driven cardiovascular diagnostics, announced that its PMcardio STEMI AI ECG model has received Breakthrough Device Designation from the FDA. This recognition highlights PMcardio's innovation in detecting ST-elevation myocardial infarction (STEMI) and STEMI equivalents, conditions that require urgent intervention. • In September 2024, GE HealthCare (Nasdaq: GEHC) announced FDA approval of FLYRCADO (flurpiridaz F 18), the first positron emission tomography myocardial perfusion imaging (PET MPI) agent for detecting coronary artery disease (CAD). Flyrcado offers superior diagnostic efficacy compared to the widely used single-photon emission computed tomography (SPECT) MPI, enhancing access to PET MPI and improving accuracy, particularly in challenging cases like high BMI patients and women. • Emerging acute myocardial infarction drugs include Selatogrel, Dutogliptin, Olpasiran, FDY-5301, Ziltivekimab, Milvexian, Zalunfiban, KAND567, ProtheraCytes, and others. • Leading companies in the acute myocardial infarction market include Idorsia Pharmaceuticals, Viatris, AstraZeneca, Boehringer Ingelheim and Eli Lilly and Company, Amgen and Arrowhead Pharmaceuticals, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, Novo Nordisk, Bristol Myers Squibb and Johnson & Johnson Innovative Medicine, Recardio, CeleCor Therapeutics, Kancera, CellProthera and BioCardia, Mesoblast, Boehringer Ingelheim, and others. To know in detail about the acute myocardial infarction market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Acute Myocardial Infarction Market Forecast Acute Myocardial Infarction Overview Acute Myocardial Infarction (AMI) refers to the death of heart muscle tissue due to the sudden blockage of a coronary artery. Common symptoms include chest pain, shortness of breath, nausea, and sweating. Diagnosis is based on electrocardiogram (ECG) findings and cardiac biomarkers. Treatment typically involves antiplatelet and anticoagulant medications, nitrates, beta-blockers, statins, and timely reperfusion therapies. In ST-segment elevation myocardial infarction (STEMI), emergency reperfusion is achieved through fibrinolytics, percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG). In non-ST-segment elevation myocardial infarction (NSTEMI), PCI or CABG is also used. AMI remains a leading cause of mortality in developed nations and is classified into two main types: STEMI and NSTEMI. While unstable angina shares similarities with NSTEMI, it does not show elevated cardiac biomarkers. Get a free sample of the acute myocardial infarction market report with key insights and emerging therapies here: Acute Myocardial Infarction Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Acute Myocardial Infarction Epidemiology Segmentation: The Acute Myocardial Infarction epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by: • Total Incident Cases of AMI • Type-Specific Incident Cases of AMI • Gender-Specific Incident Cases of AMI Download the report to understand which factors are driving acute myocardial infarction epidemiology trends @ Acute Myocardial Infarction Epidemiology Forecast Acute Myocardial Infarction Drugs Uptake, and Pipeline Development Activities The acute myocardial infarction drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the acute myocardial infarction market or expected to be launched during the study period. The analysis covers the acute myocardial infarction market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the acute myocardial infarction pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Acute Myocardial Infarction Market Strengths • Strong pipeline with innovative therapies targeting inflammation, thrombosis, and cardiac repair. • High disease burden and awareness ensure steady demand for treatment and care. Acute Myocardial Infarction Market Weaknesses • High treatment costs limit access in low- and middle-income regions. • Delayed diagnosis and limited emergency care affect outcomes in underserved areas. Scope of the Acute Myocardial Infarction Market Report • Study Period: 2020–2034 • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] • Key Acute Myocardial Infarction Therapies: Selatogrel, Dutogliptin, Olpasiran, FDY-5301, Ziltivekimab, Milvexian, Zalunfiban, KAND567, ProtheraCytes, and others. • Key Acute Myocardial Infarction Companies: Pharmaceuticals, Viatris, AstraZeneca, Boehringer Ingelheim and Eli Lilly and Company, Amgen and Arrowhead Pharmaceuticals, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, Novo Nordisk, Bristol Myers Squibb and Johnson & Johnson Innovative Medicine, Recardio, CeleCor Therapeutics, Kancera, CellProthera and BioCardia, Mesoblast, Boehringer Ingelheim, and others. • Acute Myocardial Infarction Therapeutic Assessment: Acute myocardial infarction, currently marketed, and acute myocardial infarction emerging therapies • Acute Myocardial Infarction Market Dynamics: Acute myocardial infarction market drivers and Acute Myocardial Infarction market barriers • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies • Acute Myocardial Infarction Unmet Needs, KOL's views, Analyst's views, Acute Myocardial Infarction Market Access and Reimbursement To learn more about the key players and advancements in the acute myocardial infarction treatment landscape, visit the Acute Myocardial Infarction Market Analysis Report Table of Contents 1. Acute Myocardial Infarction Market Report Introduction 2. Executive Summary for Acute Myocardial Infarction 3. SWOT analysis of Acute Myocardial Infarction 4. Acute Myocardial Infarction Patient Share (%) Overview at a Glance 5. Acute Myocardial Infarction Market Overview at a Glance 6. Acute Myocardial Infarction Disease Background and Overview 7. Acute Myocardial Infarction Epidemiology and Patient Population 8. Country-Specific Patient Population of Acute Myocardial Infarction 9. Acute Myocardial Infarction Current Treatment and Medical Practices 10. Acute Myocardial Infarction Unmet Needs 11. Acute Myocardial Infarction Emerging Therapies 12. Acute Myocardial Infarction Market Outlook 13. Country-Wise Acute Myocardial Infarction Market Analysis (2020–2034) 14. Acute Myocardial Infarction Market Access and Reimbursement of Therapies 15. Acute Myocardial Infarction Market Drivers 16. Acute Myocardial Infarction Market Barriers 17. Acute Myocardial Infarction Appendix 18. Acute Myocardial Infarction Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Jatin Vimal Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
Yahoo
25-03-2025
- Health
- Yahoo
Powerful Medical Receives FDA Breakthrough Device Designation for PMcardio STEMI AI ECG Model
NEW YORK, March 25, 2025--(BUSINESS WIRE)--Powerful Medical, a leader in AI-driven cardiovascular diagnostics, announces that its PMcardio STEMI AI ECG model has been granted Breakthrough Device Designation by the US Food and Drug Administration (FDA). This designation recognizes PMcardio as a breakthrough technology for the detection of ST-elevation myocardial infarction (STEMI) and STEMI equivalents—a life-threatening cardiac condition requiring immediate intervention. Every 40 seconds, someone in the US suffers from a heart attack¹, where rapid diagnosis is crucial to saving heart muscle and preventing long-term damage, often leading to higher mortality rates. The ECG remains the primary tool for rapid diagnostics, yet the standard of care often fails to detect heart attacks accurately and timely, resulting in critical delays in treatment. PMcardio is the only solution capable of detecting both STEMI and STEMI equivalents on the ECG—aligning with the emerging emphasis on a paradigm shift towards Occlusion Myocardial Infarction (OMI) diagnosis and bridging a vital gap in early, precise heart attack diagnosis. "For the last 20 years, life-saving treatment exists for heart attack patients, yet far too many still don't receive the urgent care they need due to delays in diagnosis and inefficient triage," said Robert Herman, MD, PhD, Chief Medical Officer of Powerful Medical. This is especially critical in settings where immediate specialist evaluation isn't available—only 17% of patients presenting to rural centers make it to the catheterization lab in time for intervention.² Dr. Herman added, "By equipping physicians and allied providers with an AI-powered tool for accurate and immediate STEMI detection, available around the clock, we can bridge this gap, ensure timely treatment, and improve patient outcomes, often preventing avoidable deaths". The FDA's Breakthrough Device Designation provides PMcardio with an expedited review process and close collaboration with the agency on its path toward market authorization. This designation is reserved for technologies that offer significant advantages over existing solutions and address unmet medical needs. This recognition underscores the FDA's acknowledgment of Powerful Medical's STEMI AI ECG Model, dubbed "Queen of Hearts", to set a new standard in frontline heart attack detection and triage, ultimately enhancing care quality, accelerating treatment decisions, and saving lives through earlier and more accurate diagnosis. "FDA Breakthrough Device Designation is a pivotal milestone in our effort to revolutionize heart attack detection and ensure every patient receives immediate, life-saving care," said Felix Bauer, COO of Powerful Medical. "We're committed to bringing this life-saving technology to the US, the largest healthcare market in the world. This recognition by the FDA validates the impact of our innovation and brings us closer to transforming emergency cardiac care on a global scale," added Martin Herman, CEO. With this designation, Powerful Medical not only works closely with the FDA on market approval but also gains improved access to CMS reimbursement mechanisms to bring the PMcardio STEMI AI ECG Model to healthcare providers nationwide, serving US public health. About Powerful Medical Powerful Medical is a pioneering health technology company specializing in AI-driven cardiovascular diagnostics. Its flagship product, PMcardio, harnesses AI to enhance ECG interpretation, streamline patient triage, and support clinical decision-making. With a mission to bridge the gap between innovation and clinical practice, Powerful Medical is committed to ensuring every patient receives the highest standard of care. References Tsao, C.W., Aday, A.W., et al. Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association. Circulation. 2023. Jollis, J.G., Granger, C.B., et al. Treatment time and in-hospital mortality among patients with ST-segment elevation myocardial infarction. JAMA. 2018–2021. View source version on Contacts Lucia Bojkovskapr@ Sign in to access your portfolio
